Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice.
The reduction of glomerular filtration rate (GFR) below 50% of normal has been associated with a progressive loss of kidney function, even after the original disease becomes inactive [1, 2] . There have been reports that up to 30% of patients with greater then 50% reduction of total renal mass develop systemic hypertension and 70% develop significant proteinuria, in some cases leading to end-stage renal disease (ESRD) [3, 4] . However, since most patients after unilateral nephrectomy are able to maintain normal kidney function it is clear that additional nonimmune mechanisms are important in the pathogenesis of chronic renal injury. Here, we assess the effects of two physiologic processes, reduced renal mass and hyperlipidemia, that have both been strongly implicated as key mediators of progressive renal injury. To study the role of reduced renal mass we utilized the ROP Os/+ mouse strain, which carries a radiation-induced mutation of the Os gene located on chromosome 8 [5, 6] . A homozygous mutation in this locus is associated with early postimplantation lethality, whereas heterozygous mice develop oligosyndactyly and 38% reduction in renal mass [7] . Mice develop an approximately 50% decrease in nephron number with a compensatory increase in glomerular volume and tubular hypertrophy [7] . This increase in glomerular volume is due to a significant expansion of the mesangial matrix area with accumulation of collagen IV and tenascin as well as an increase in glomerular cell number and concomitantly increased thymidine labeling index [8] . The Os mutation was originally described in ROP mice, which were shown to be a sclerosis prone strain [9, 10] . The B6.ROP Os/+ strain has all the biologic features of the Os mutation but is on a C57BL/6 genetic background, and not on a ROP background, despite the similarities in nomenclature. This strain is neutral with respect to susceptibility to glomerulosclerosis, and is more resistant to sclerosis than the ROP strain originally used for studies of the renal effects of the Os mutation.
Abnormal lipid metabolism frequently accompanies renal disease and is thought to be involved in the pathogenesis of renal injury. Clinical observations have suggested a role of hyperlipidemia as a modulator of progression of primary kidney diseases. Nondiabetic patients with proteinuria and elevation in serum cholesterol and triglycerides had a nearly twofold increase in the rate of loss of renal function compared to normolipidemic patients [11, 12] and treatment with lipid-lowering agents has been demonstrated to reduce levels of circulating cholesterol and to stabilize or improve renal function [13] [14] [15] . However, the relationship between hyperlipidemia and renal injury remains incompletely understood. The aim of this study was to gain further insight into the effects of hyperlipidemia on renal pathology and kidney function in a model of reduced renal mass, the B6.ROP Os/+ mouse.
METHODS

Animal study and experimental design
Female C57BL/6 and male B6.ROP Os/+ mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). C57BL/6 females were bred with the B6.ROP Os/+ males to generate mice heterozygous for the Os gene. Female C57BL/6 control mice and B6.ROP Os/+ were fed either a rodent chow diet (N = 5 and N = 6, respectively), or a high fat, high cholesterol (HFHC) diet (N = 5, and N = 8, respectively) as described below. Mice were maintained in a temperature-controlled room (22
• C) with a 12-hour light/dark cycle and given free access to food and water. Food was removed from the mice 4 hours prior to the collection of blood from the retroorbital sinus into tubes containing anticoagulant [1 mmol/L ethylenediaminetetraacetic acid (EDTA)]. Plasma was stored at −70
• C until analysis. Mice were killed by cervical dislocation and tissues were snap frozen in liquid nitrogen and stored at −70 • C.
Diets and feeding
Two diets were used in this study. The first was pelleted rodent chow (Wayne Rodent BLOX 8604), which served as a reference diet and contained by weight approximately 4% fat, 24% protein, and 4.5% crude fiber (manufacturer's estimates). All mice were fed the rodent chow diet until 20 weeks of age when the test diet was initiated in the experimental group. The test diet was a HFHC diet that contained 15% fat, 1.25% cholesterol, and 0.5% sodium cholate (TD 92001) (Harlan Teklad, Madison WI, USA). Mice were fed the HFHC diet for 12 weeks.
Analytical procedures
Total plasma cholesterol was assessed colorimetrically using a kit from Diagnostic Chemicals Limited (Diagnostic Chemicals Limited, Oxford, CT, USA) with cholesterol standards (Preciset #12552) (Boehringer Mannheim, Indianapolis, IN, USA). Plasma triglyceride levels were determined after the removal of free glycerol using a colorimetric kit (Diagnostic kit # 450032) (Boehringer Mannheim). Plasma blood urea nitrogen (BUN) levels were measured using a colorimetric assay from Sigma (Diagnostic kit #535-A) (Sigma Chemical Co., St. Louis, MO, USA). Urinary protein excretion was assessed with urine test strips (Uristix) (Bayer, Elkhart, IN, USA) in a semiquantitative fashion. Glucose and insulin levels were measured at the Northwest Lipid Research Laboratories, University of Washington.
Tissue preparation and histologic staining
At the end of the study mice were sacrificed by cervical dislocation and whole animals were perfused with 10 mL of antioxidant buffer [100 lmol/L diethylenetriame pentaacetic acid (DTPA), 100 lmol/L, butylated hydroxytoluene (BHT), and 0.1% ethanol in phosphatebuffered saline (PBS), pH 7.4] via the left ventricle. Kidneys were removed and fixed in 10% neutral buffered formalin or methyl Carnoy's solution (60% methanol, 30% chloroform, and 10% acetic acid) for histologic examination. Small portions of kidney tissue were fixed in half strength Karnovsky's solution for electron microscopy (1% paraformaldehyde and 1.25% glutaraldehyde in 0.1 mol/L Na cacodylate buffer, pH 7.0). Tissues were processed and embedded in paraffin using standard protocols and cut into 2 lm sections for periodic acid-methenamine silver stain (PAM) or in 4 lm sections for hematoxylin and eosin staining, immunohistochemistry or terminal deoxy transferase uridine triphosphate nick end labeling (TUNEL) staining.
Immunohistochemistry and TUNEL staining
Tissue sections were deparaffinized in xylene and rehydrated in graded ethanol to use for immunohistochemistry. Where necessary, antigen retrieval was performed by heating tissue sections in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, USA). Endogenous peroxidases were blocked by immersing the tissue in 3% hydrogen peroxide and endogenous biotin was blocked using the Avidin/Biotin blocking kit (Vector Laboratories). Primary antibodies were diluted in 1% bovine serum albumin (BSA) (Sigma Chemical Co.) in PBS and sections were incubated for 1 hour at room temperature. After repeated washing steps slides were incubated with the appropriate biotinylated secondary antibody for 30 minutes. Signal amplification was performed with the Vector ABC-Elite Reagent and 3, 3 -diaminobenzidine (DAB) (Sigma Chemical Co.) with nickel enhancement was used a chromogen resulting in a black color product. Tissue sections were counterstained with periodic acid-Schiff (PAS)/methyl green, dehydrated and coverslipped.
Macrophages were detected with a rat anti-mouse Mac-2 antibody from Cederlane (Cederlane, Ontario, Canada) as described previously [16] . Mesangial cell activation and smooth muscle-like transformation was assessed with a mouse monoclonal IgG 2a antibody against a-smooth muscle actin (a-SMA) (clone 1A4) (Dako, Carpenteria, CA, USA), previously described in [17] . An antibody against human proliferating cell nuclear antigen (PCNA) (Oncogene Research Products, Cambridge, MA, USA) was used to show cellular proliferation (previously described in [18] ). Glomerular apolipoprotein B deposition was stained with a rabbit polyclonal antibody generously provided by J. Born. Appropriate secondary antibodies were all from Vector Laboratories except for antimouse IgG 2a , which was purchased from Pharmingen (San Diego, CA, USA).
TUNEL staining was performed using the TdT-FragEL DNA fragmentation detection kit (Oncogene Research Products) according to the manufacturer's instructions and previously described in detail [19] . In brief, tissue sections were deparaffinized, rehydrated, and permeabilized in 20 lg/mL proteinase K in 10 mmol/L Tris. Endogenous peroxidases were blocked in 3% hydrogen peroxide in methanol. After that slides were labeled with TdT labeling reaction mix and incubated for 1.5 hours at 37
• C. The resulting signal was amplified with the ABC-Elite reagent (Vector Laboratories) and visualized with DAB and nickel enhancement. Finally, the slides were counterstained with PAS and methyl green, dehydrated, and coverslipped.
In situ hybridization
In situ hybridization was performed on formalin fixed tissue after washing in 0.5× standard saline citrate (SSC) (1× SSC = 150 mmol/L NaCl and 15 mmol/L Na citrate, pH 7.0) and digestion with 25 lg/mL proteinase K (Sigma Chemical Co.) for 30 minutes at 37
• C. Several washes with 0.5× SSC are followed by a 2-hour incubation with prehybridization buffer [0.3 mol/L NaCl, 20 mmol/L Tris, pH 8.0, 5 mmol/L EDTA, 1× Denhardt's solution, 10% dextran sulfate, and 10 mmol/L dithiothreitol (DTT)]. The hybridization process was started by adding 500,000 cpm 35 S-labeled probe in prehybridization buffer to the slides and allowed to proceed overnight at 50
• C. After hybridization the slides were washed in 2× SSC and treated with RNase A (20 lg/mL). Rinsing in 2× SSC was followed by three high-stringency washing steps in 0.1× SSC + 0.1% Tween 20 (Sigma Chemical Co.) at 50
• C and several 2× SSC washes. The tissue was then dehydrated in graded ethanol, air-dried, and dipped in NTB2 nuclear emulsion (Kodak, Rochester, NY, USA). Slides were exposed in the dark for 2 to 5 weeks at 4
• C. After developing the sections were counterstained with hematoxylin and eosin.
Probes used for in situ hybridization were transforming growth factor-b (TGF-b1), platelet-derived growth factor-B (PDGF-B), PDGF receptor b, and monocyte chemoattractant protein-1 (MCP-1) and have been described in detail [20] .
Electron microscopy
Randomly selected cases of each experimental group were utilized for electron microscopy and processed as described previously in detail [21] . Grids were scanned using a Philips 410 electron microscope (Philips, Eindhoven, The Netherlands).
Quantitative analysis and statistics
Morphometric analysis was performed by using the Image Pro Plus software (Media Cybernetics, Silver Spring, MD, USA). Fifteen random glomerular cross-sections per experimental animal were photographed by a blinded examiner using a digital camera (Olympus DP11) (Olympus America, Melville, NY, USA). Hematoxylin and eosin-stained sections were used for the assessment of glomerular cellularity while the amount of extracellular matrix was evaluated using PAM silver stains and immunohistochemistry for collagen IV. The number of macrophages and proliferating cells was counted in at least 20 random glomerular cross-sections or high power fields. Glomerular a-SMA expression in mesangial areas was assessed semiquantitatively on a scale from 0 (negative) to 4 (strong global expression) as previously described [22] . Intraglomerular expression of mRNA for different probes was scored using a similar semiquantitative system in which 0 corresponded to no expression, 1 to only a few positive cells, 2 to several positive cells, and 3 to many positive cells in a diffuse distribution.
Values are expressed as mean ± SEM. Statistical differences were calculated using the SPSS software (SPSS Inc., Chicago, IL, USA). Means between groups were compared using analysis of variance (ANOVA) with Tukey's post hoc test. A P value of P < 0.05 was considered statistically significant. Association between PDGF-B and glomerular cellularity as well as TGF-b and glomerular matrix and collagen IV expression was calculated using the nonparametric Spearman rank correlation coefficient.
RESULTS
Hyperlipidemia reduced kidney function and induced renal pathology in C57BL/6 mice
Feeding of a HFHC diet to C57BL/6 mice led to a significant increase in plasma cholesterol from 63 ± 4 mg/dL in control animals to 249 ± 27 mg/dL in the HFHC diet (P < 0.01) ( Table 1) while plasma triglycerides levels decreased from 36 ± 5 mg/dL for controls to 9 ± 1 mg/dL in animals on the HFHC diet. These changes in lipid metabolism were accompanied by a significant increase in plasma BUN in the hyperlipidemic group (26 ± 2 mg/dL in controls vs. 41 ± 4 mg/dL in hyperlipidemic animals) (P < 0.05) ( Table 1 ) and a significant increase Abbreviations are: gcs, glomerlar cross-section; hpf, high power field; PCNA, proliferating cell nuclear antigen; TUNEL, terminal deoxy transferase uridine triphosphate nick end labeling.
Morphometric analysis of kidney sections from chow-fed wild-type and B6.ROP Os/+ mice and C57BL/6 and B6.ROP Os/+ animals on a high fat diet. Data expressed as mean ± SEM. Statistical significances compared to wild-type controls ( a P < 0.05, b P < 0.01, c P < 0.001) or compared to chow fed B6.ROP Os/+ animals ( d P < 0.05, e P < 0.01, f P < 0.001). Statistically significant differences between both hyperlipidemic groups are expressed as g P < 0.05 and h P < 0.01.
in urinary protein excretion (0.4 ± 0.2 units in C57BL/6 mice vs. 1.4 ± 0.2 units in mice fed the HFHC diet) (P < 0.05) ( Table 1) . This decline in kidney function by hyperlipidemia correlated with the induction of renal pathology in C57BL/6 mice. Hyperlipidemic mice showed modest amounts of glomerular staining for apolipoprotein B, which was absent in normolipidemic mice (Fig. 5) . Glomerular lesions were represented by an increase in mesangial a-SMA expression (score of 0.0 ± 0.0 in wild-type mice vs. 0.2 ± 0.0 in animals fed the HFHC diet) (P < 0.05) ( Table 2 ) (Fig. 3) . This indication of mesangial cell activation corresponded to a twofold increase in mesangial matrix (P < 0.01) and glomerular collagen IV (P < 0.001) in hyperlipidemic mice compared to normal control mice (Table 2) (Fig. 1) . Glomeruli of hyperlipidemic C57BL/6 mice also demonstrated modest hypercellularity with an increase in cell number from 43 ± 2 cells/glomerular cross-section in control mice to 58 ± 1 cells/glomerular cross-section in animals fed the HFHC diet (P < 0.01) (Table 2) (Fig. 1) . Proliferation and apoptotic cell death, assessed by PCNA and TUNEL staining, were not different between mice on normal chow and animals fed a HFHC diet. Glomerular macrophage content was only slightly elevated in hyperlipidemic mice compared to controls but glomerular macrophages had frequently foam cell appearance (Table 2) (Fig. 2) .
In addition to the glomerular changes induced by hyperlipidemia, mice on the HFHC diet also demonstrated tubulointerstitial pathology. Hyperlipidemic mice showed occasional staining for apolipoprotein B in infiltrating cells in the tubulointerstitium, morphologically most likely representing macrophages (Fig. 5) . They had a large influx of macrophages into the tubulointerstitium (3.6 ± 0.4 mac-2-positive cells/high power field vs. 0.2 ± 0.0 cells/high power field in control mice) (P < 0.01) ( Table 2) (Fig. 4) . Hyperlipidemic mice showed signs of fatty degeneration of the tubular epithelium and cellular proliferation was significantly increased in the tubular epithelium (1.2 ± 0.3 PCNA positive cells/high power field in control mice vs. 7.4 ± 0.8 cells/high power field in mice fed the HFHC diet) (P < 0.01) ( Table 2) . B6.ROP Os/+ mice showed glomerular hypertrophy and mesangial accumulation of extracellular matrix B6.ROP Os/+ mice demonstrated a significant decline in renal function compared to C57BL/6 control mice. Plasma BUN levels were elevated to 45 ± 4 mg/dL compared to 26 ± 2 mg/dL in controls (P < 0.01) ( Table 1) and proteinuria increased from 0.4 ± 0.2 × in C57BL/6 animals to 1.5 ± 02 × in mice with the Os gene (P < 0.01) ( Table 1) . Plasma cholesterol and triglycerides levels remained unchanged.
Renal pathology was remarkable for glomerular hypertrophy, demonstrated by an increase in glomerular size (3679 ± 134 lm 2 in controls vs. 6045 ± 383 lm 2 in B6.ROP Os/+ mice) (P < 0.001) ( Table 2) (Fig. 1) . This increase in glomerular area resulted from an increase in cellularity (43 ± 2 cells/glomerular cross-section in control mice vs. 64 ± 4 cells/glomerular cross-section in B6.ROP Os/+ mice) (P < 0.001) and accumulation of extracellular matrix. The hypercellularity was the result of an increase in cell proliferation as assessed by PCNA stain (P < 0.05) ( Table 2) , as well as an influx of macrophages (1.2 ± 0.2 macrophages/glomerular cross-section in control mice vs. 3.6 ± 0.7 cells/glomerular cross-section in B6.ROP Os/+ mice) (P < 0.01). The silver-stained area of the glomerulus, representing extracellular matrix, increased from 179 ± 15 lm 2 in wild-type animals to 355 ± 29 lm 2 in B6.ROP Os/+ mice (P < 0.01) ( Table 2) (Fig. 1) . A similar increase was noted for collagen IV, an important component of ex- tracellular matrix (237 ± 24 lm 2 in C57BL/6 controls vs. 563 ± 28 lm 2 ) (P < 0.001). The a-SMA score, a measure for mesangial cell activation, was also elevated in B6.ROP Os/+ mice (P < 0.001) ( Table 2) (Fig. 3) . No significant staining for apolipoprotein B could be detected in the glomeruli or the tubulointerstitium of B6.ROP Os/+ mice.
The tubular parenchyma showed a modest degree of tubular dilation and atrophy. The tubulointerstitium demonstrated high number of macrophages (P < 0.05) ( Table 2) (Fig. 2) . Cellular turnover of tubular epithelial cells was not changed compared to control mice. No significant fibrosis was noted.
Hyperlipidemia led to a further decline in renal function in B6.ROP Os/+ mice
Feeding of the HFHC diet led to a significant increase in plasma cholesterol in B6.ROP Os/+ mice (361 ± 41 mg/dL with HFHC diet vs. 71 ± 3 mg/dL on regular chow) (P < 0.001) ( Table 1) . Triglyceride levels were decreased by the HFHC diet (36 ± 5 mg/dL on normal diet vs. 18 ± 3 mg/dL on the HFHC diet) (P < 0.01). Hyperlipidemic B6.ROP Os/+ mice had a further decline in renal function compared to normolipidemic B6.ROP Os/+ animals as expressed by an increase of plasma BUN from 45 ± 4 mg/dL on the chow diet to 62 ± 2 mg/dL on the HFHC diet (P < 0.05) but proteinuria remained unchanged to the elevated levels of normolipidemic B6.ROP Os/+. 
Hyperlipidemia aggravated renal pathology in B6.ROP Os/+ mice
Hyperlipidemic B6.ROP Os/+ mice had significant glomerular hypertrophy compared to wild type mice (5414 ± 159 lm 2 vs. 3679 ± 134 lm 2 in C57BL/6 animals) (P < 0.001) but glomerular architecture was more altered then in normolipidemic B6.ROP Os/+ animals. Glomeruli frequently displayed signs of mesangiolysis; a-SMA expression, although still elevated compared to C57BL/6 control mice, was decreased in these areas (Table 2) (Fig. 3) . Glomeruli commonly showed mesangial lipid deposits and diffuse or focal staining for apolipoprotein B (Fig. 5) , mostly in the area of the vascular pole. Glomerular extracellular matrix increased from occupying 5.8 ± 0.3% to 7.1 ± 0.3% of the glomerular area in hyperlipidemic mice (P < 0.05) and glomerular collagen IV expression increased from 8.7 ± 0.2% to 12.2 ± 0.4% in animals fed the HFHC diet compared to normolipidemic B6.ROP Os/+ mice (P < 0.05). In addition, hypercellularity also increased in hyperlipidemic B6.ROP Os/+ mice compared to normolipidemic controls from a cellular area of 10.5 ± 0.5% of the glomerulus to 12.4 ± 0.2%, respectively (P < 0.01) ( Table 1) . However, glomerular proliferation rate was unchanged and glomerular macrophage content was even slightly lower then in normolipidemic mice (2.0 ± 0.1 mac-2-positive cells/glomerular cross-section vs. 3.6 ± 0.7 mac-2-positive cells/glomerular cross-section in chowfed B6.ROP Os/+ mice) (P < 0.05) (Fig. 2 ) though macrophages were mostly foam cell-like in appearance and sometimes demonstrated staining for apolipoprotein B (Fig. 5) .
Tubulointerstitial changes in hyperlipidemic B6.ROP Os/+ animals included fatty tubular degeneration in addition to the tubular atrophy and dilation seen in B6.ROP Os/+ mice on a regular diet. Tubular epithelial cells had a significantly increased cell turnover with PCNA staining cells being increased from 1.8 ± 0.2/high power field in normolipidemic mice to 9.8 ± 1.4 positive cells/high power field in hyperlipidemic B6.ROP Os/+ animals (P < 0.001) (Fig. 4) and tubular TUNEL staining was also elevated although they did not reach the level of statistical significance (0.1 ± 0.0 TUNEL-positive cells/high power field in B6.ROP Os/+ mice vs. 0.6 ± 0.0 TUNEL-positive cells/high power field in B6.ROP Os/+ mice on the HFHC diet) (P = 0.099) (Fig. 4) . Tubulointerstitial macrophage influx was elevated compared to C57BL/6 control mice and macrophages had mostly a foam cell-like phenotype (0.2 ± 0.0 in control animals vs. 3.7 ± 0.5 cells/high power field in hyperlipidemic B6.ROP Os/+ mice) (P < 0.001). The tubulointerstitium also showed infiltrating cells that stained positive for apolipoprotein B (Fig. 5) .
Influences of the ROP Os/+ mutation on kidney function and renal pathology in hyperlipidemic mice
Reduction of renal mass by the ROP mutation led to an increase in plasma BUN in B6.ROP mice on the HFHC diet compared to wild-type mice on HFHC diet while proteinuria was not further increased (Table 1) . Glomerular injury in hyperlipidemic B6.ROP mice seemed to be aggravated compared to wild-type mice on the HFHC diet as expressed by an increase in glomerular size and glomerular collagen IV accumulation (Table 2) (Fig. 1) . In addition, glomerular a-SMA expression was increased in hyperlipidemic B6.ROP mice compared to hyperlipidemic wild-types (Fig. 3) . The reduction in glomerular mass induced by the ROP Os/+ mutation seemed to have no influence on glomerular macrophages, proliferating cells, or apoptotic cells which were not different between both hyperlipidemic groups. Markers of tubulointerstitial changes like macrophage influx and tubuloepithelial cell turnover measured in proliferating and apoptotic cells were also not significantly different between these two groups.
Electron microscopy
Electron microscopy in a few selected cases showed an expansion of the mesangium in chow-fed B6.ROP Os/+ mice with an increase in actin filaments. Mesangial areas displayed frequent infiltration with macrophages. Hyperlipidemia led to the deposition of fat in the mesangial matrix and in the subendothelial areas of capillary walls as well as to the infiltration of the mesangium with macrophages with a foam cell appearance (Fig. 6) .
Renal pathology was associated with changes in the expression levels of glomerular cytokines and chemokines
In situ hybridization was performed to assess whether changes in renal pathology were mediated by glomerular expression of different cytokines and chemokines. Glomerular expression of TGF-b mRNA was increased in hyperlipidemic C57BL/6 mice, B6.ROP Os/+ mice, and hyperlipidemic B6.ROP Os/+ animals (relative scores of 0.2 ± 0.1 in normal controls to 1.6 ± 0.2, 1.3 ± 0.2, and 1.4 ± 0.1, respectively) (P < 0.001). The intraglomerular expression of TGF-b mRNA correlated with the amount of extracellular matrix assessed by black staining material in PAM stain (r = 0.53, P < 0.01) and with glomerular collagen IV content (r = 0.59, P < 0.01). It also showed a significant association with intraglomerular macrophage content (r = 0.55, P < 0.01), which has previously shown to be a contributor to total glomerular TGF-b expression [23, 24] .
Similarly, hyperlipidemic control mice and ROP Os/+ mice showed a strong increase in glomerular PDGF-B mRNA expression and its receptor PDGF receptor b with a further increase in hyperlipidemic ROP Os/+ animals (Table 3) . Both, PDGF-B and its receptor, correlated with glomerular cellularity (r = 0.63, P < 0.01 and r = 0.5, P < 0.05, respectively).
Renal expression of the chemoattractant MCP-1 was generally low with no positive cells in control mice and Consequently, no statistical analysis was not performed for this parameter.
Hyperlipidemic mice do not develop obesity, hyperglycemia, and insulin resistance
To assess whether the deterioration in renal function and the aggravation of renal pathology was due to hyperlipidemia and not to changes mediated by obesity, hyperglycemia, or insulin resistance, body weight as well as glucose and insulin levels were assessed in mice from all experimental groups. Feeding a HFHC diet to C57BL/6 wild-type mice did not induce an increase in body weight and did not influence glucose metabolism as indicated by serum glucose and insulin levels (Table 1) as previously described [25] . Similarly, feeding this diet to B6.ROP Os/+ mice did not induce obesity (22.3 ± 1.2 g body weight in chow fed B6.ROP Os/+ mice vs. 19.2 ± 0.5 g in B6.ROP Os/+ mice on the HFHC diet) and there was no increase in glucose or insulin levels induced by feeding the HFHC diet (Table 1) .
DISCUSSION
The capacity of hyperlipidemia to initiate or significantly contribute to chronic renal injury remains unsettled. In humans the role of hyperlipidemia in initiating kidney disease seems to be limited to some rare forms of metabolic abnormalities such as lecithin:cholesterol acyltransferase (LCAT) deficiency [26] and disorders of apolipoprotein E [27] . The extent to which hyperlipidemia might contribute to such chronic renal injury as diabetes or nephrosclerosis is not yet clear. The situation is different in experimental settings where hyperlipidemia has been demonstrated to induce renal injury in a variety of animal models such as dietary induced hyperlipidemia in rat [28] [29] [30] , guinea pig [31] , and rabbit [32] , as well as in genetic hyperlipidemia in the obese Zucker rat [33] and the apolipoprotein E −/− mouse [34] . In this study we examined the effect of hyperlipidemia in mice with reduced nephron mass, a situation common in humans as a result of aging, remote glomerulonephritis, vascular disease, or nephrectomy. We demonstrate that feeding a HFHC diet to C57BL/6 mice led to a decline in renal excretory function and to the development of proteinuria. These changes correlated with an increase in mesangial matrix and cellularity and by tubulointerstitial alterations including macrophage influx and an increased turnover of tubular epithelial cells. In addition, we could establish that hyperlipidemia aggravates renal injury in B6.ROP Os/+ mice. Hyperlipidemic B6.ROP Os/+ animals had an additional increase in plasma BUN levels and showed augmentation of ROP Os/+ associated renal pathology with the presence of mesangiolysis and a further increase in glomerular matrix and cellularity compared to normolipidemic B6.ROP Os/+ mice. Tubulointerstitial changes consisted of fatty tubular degeneration with an increase in the proliferation index of tubular epithelial cells and infiltration of macrophages/foam cells.
The mechanism by which hyperlipidemia exerts its deleterious effect on the kidney is still largely unknown. One mechanism by which hyperlipidemia may mediate renal injury could be by directly acting on resident cells in the kidney. The glomerulus and the renal tubulointerstitium may be a preferred location for lipid deposition and interaction with resident cells because of the lack of a basement membrane separating the mesangium and the capillary stream and the presence of fenestrated epithelium lining glomerular and peritubular capillaries. Lipids can therefore easily access these areas and influence local metabolism. Mesangial cells have been shown to bind and take up native and oxidized low-density lipoprotein (LDL) cholesterol [35] . Binding of LDL and other lipoproteins to mesangial cells has been shown to influence cellular proliferation and stimulate secretion of inflammatory mediators like prostanoids, interleukin-6 (IL-6), PDGF, and TGF-b [35] [36] [37] [38] . In addition, lipoproteins influence matrix generation by stimulating mesangial fibronectin and collagen IV expression [39, 40] . Consistent with this scenario, we were able to demonstrate that hyperlipidemic mice in our study had increased levels of glomerular expression of TGF-b, PDGF-B and its receptor PDGF receptor b. The relative expression of glomerular mRNA of these cytokines was significantly correlated with the amount of glomerular matrix and cellularity, respectively, making these growth factors likely contributors to the injury process. However, our results demonstrate only a correlation and not a definitive proof of causality.
Lipoproteins, the transport entities for lipids in the blood, may play a role in renal injury as well. Apolipoprotein B has been linked to the development of atherosclerosis and cardiovascular disease [41] [42] [43] and there have also been some studies that demonstrate an association of apolipoprotein B plasma levels and the progression of renal insufficiency [12, [44] [45] [46] . Normolipidemic control and B6.ROP Os/+ mice in our study did not show significant staining for apolipoprotein B in either glomeruli or the tubulointerstitium. In contrast, hyperlipidemic C57BL/6 animals demonstrated diffuse glomerular staining for apolipoprotein B and additional staining of interstitial cells that morphologically appeared to be infiltrating macrophages. In addition to this finding, the hyperlipidemic B6.ROP Os/+ mice had frequent, focal staining for apolipoprotein B in the area of the vascular pole that could not be seen in hyperlipidemic control animals. One explanation for this distinct staining pattern could be that these mice have impaired clearing of lipids through a mesangial pathway as an indicator of glomerular injury. However, our study does not address the issue whether trapping of apolipoprotein B in the glomeruli itself is able to induce renal damage or if this localization is incidental to the principal mechanism of tissue injury.
A mechanism that may be important in the mediation of lipid-induced renal injury involves infiltrating macrophages. Lipids have been shown to induce glomerular expression of chemoattractants such as MCP-1, monocyte-colony-stimulating factor (M-CSF), migration inhibitory factor (MIF), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) [47] [48] [49] and various animal models of hyperlipidemia-induced renal disease have demonstrated increased influx of macrophages into glomeruli [28, 30, 34, 50] and into the tubulointerstitium [23, 29, 51, 52] of affected animals. The functional importance of macrophages in mediating renal injury in hyperlipidemic states is highlighted by work done by Pesek-Diamond et al [51] showing that depletion of macrophages resulted in an amelioration of renal function impairment and reduction of glomerulosclerosis and matrix expansion in hyperlipidemic rats with acute puromycin aminonucleoside nephrosis. Our studies tested this mechanism by directly assessing monocyte/macrophage infiltration and production of a major chemoattractant for these cells, MCP-1. Hyperlipidemic C57BL/6 mice in our study did not show significant expression of MCP-1 in either the glomeruli or the interstitium, corresponding to the low increase in glomerular macrophage content. However, hyperlipidemia did induce tubulointerstitial influx of macrophages/foam cells, presumably mediated by chemoattractants other than MCP-1. Studies have also indicated that macrophages from hyperlipidemic rats may be a major source for increased TGF-b expression [23, 24] , an important cytokine for mediating extracellular matrix deposition [53] . Our study also demonstrated a significant correlation between glomerular macrophage content and TGF-b expression.
CONCLUSION
We have been able to show that hyperlipidemia leads to significant renal injury associated with a decline in renal function in healthy C57BL/6 control mice and that it is able to aggravate renal injury of reduced renal mass induced by the ROP Os/+ mutation. TGF-b and the PDGF-B system have been identified as two possible mediators of this process.
